ATE486934T1 - Das shiga-ähnliche toxin enthaltende, rekombinante proteine und vaskuläre, endothel- spezifische wachstumsfaktorfragmente - Google Patents

Das shiga-ähnliche toxin enthaltende, rekombinante proteine und vaskuläre, endothel- spezifische wachstumsfaktorfragmente

Info

Publication number
ATE486934T1
ATE486934T1 AT01918834T AT01918834T ATE486934T1 AT E486934 T1 ATE486934 T1 AT E486934T1 AT 01918834 T AT01918834 T AT 01918834T AT 01918834 T AT01918834 T AT 01918834T AT E486934 T1 ATE486934 T1 AT E486934T1
Authority
AT
Austria
Prior art keywords
growth factor
toxin
shiga
vascular endothelial
directed
Prior art date
Application number
AT01918834T
Other languages
English (en)
Inventor
Marina Backer
Joseph Backer
Original Assignee
Sibtech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sibtech Inc filed Critical Sibtech Inc
Application granted granted Critical
Publication of ATE486934T1 publication Critical patent/ATE486934T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01918834T 2000-03-22 2001-03-19 Das shiga-ähnliche toxin enthaltende, rekombinante proteine und vaskuläre, endothel- spezifische wachstumsfaktorfragmente ATE486934T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19097300P 2000-03-22 2000-03-22
US09/796,861 US20010031485A1 (en) 2000-03-22 2001-03-01 Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments
PCT/US2001/008798 WO2001070945A1 (en) 2000-03-22 2001-03-19 Recombinant proteins containing shiga-like toxin and vascular endothelial growth factor fragments

Publications (1)

Publication Number Publication Date
ATE486934T1 true ATE486934T1 (de) 2010-11-15

Family

ID=26886614

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01918834T ATE486934T1 (de) 2000-03-22 2001-03-19 Das shiga-ähnliche toxin enthaltende, rekombinante proteine und vaskuläre, endothel- spezifische wachstumsfaktorfragmente

Country Status (6)

Country Link
US (1) US20010031485A1 (de)
EP (1) EP1268760B1 (de)
JP (1) JP4671574B2 (de)
AT (1) ATE486934T1 (de)
DE (1) DE60143382D1 (de)
WO (1) WO2001070945A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109167B2 (en) 2000-06-02 2006-09-19 Bracco International B.V. Compounds for targeting endothelial cells, compositions containing the same and methods for their use
US8263739B2 (en) 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
US7985402B2 (en) * 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
AU2003278807A1 (en) 2002-03-01 2004-08-13 Bracco International B.V. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7666979B2 (en) * 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
DE10210284A1 (de) * 2002-03-08 2003-10-02 Medigene Ag Verfahren zum Identifizieren von spezifischen RNA-Inhibitoren
ES2396368T3 (es) 2003-03-03 2013-02-21 Dyax Corporation Péptidos que se unen específicamente al receptor del HGF (CMET) y usos de los mismos
US7807184B2 (en) 2003-07-21 2010-10-05 Interuet International B.V. Hybrid Shiga-like toxin
CN103045633A (zh) * 2012-12-11 2013-04-17 中国科学院广州生物医药与健康研究院 重组人血管内皮细胞生长因子-165蛋白及其生产方法
EP3666795A1 (de) 2013-03-12 2020-06-17 Molecular Templates, Inc. Zytotoxische proteine mit zellgerichteten bindungsregionen und shigatoxin-a-untereinheitsregionen zur selektiven tötung von spezifischen zellarten
CN112851769A (zh) * 2014-01-27 2021-05-28 分子模板公司 用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
CN106604934A (zh) 2014-06-11 2017-04-26 分子模板公司 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
EP3253799B1 (de) 2015-02-05 2020-12-02 Molecular Templates, Inc. Multivalente cd20-bindende moleküle mit shigatoxin-a-untereinheiteffektorregionen und angereicherte zusammensetzungen davon
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3303373B1 (de) 2015-05-30 2020-04-08 Molecular Templates, Inc. Deimmunisierte shigatoxin-a-untereinheitsgerüste und zellgerichtete moleküle damit
WO2018106895A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MX2019008840A (es) 2017-01-25 2019-09-09 Molecular Templates Inc Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
CN110612117B (zh) 2018-04-17 2024-04-12 分子模板公司 包含去免疫化的志贺毒素a亚基支架的her2靶向分子

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment

Also Published As

Publication number Publication date
DE60143382D1 (de) 2010-12-16
WO2001070945A1 (en) 2001-09-27
JP4671574B2 (ja) 2011-04-20
JP2003533980A (ja) 2003-11-18
EP1268760B1 (de) 2010-11-03
EP1268760A1 (de) 2003-01-02
US20010031485A1 (en) 2001-10-18
EP1268760A4 (de) 2004-07-14

Similar Documents

Publication Publication Date Title
ATE486934T1 (de) Das shiga-ähnliche toxin enthaltende, rekombinante proteine und vaskuläre, endothel- spezifische wachstumsfaktorfragmente
Kao et al. A peptide derived from the amino terminus of endothelial-monocyte-activating polypeptide II modulates mononuclear and polymorphonuclear leukocyte functions, defines an apparently novel cellular interaction site, and induces an acute inflammatory response
UA90657C2 (ru) Ловушки vegf и их терапевтические применения
FR19C1020I1 (fr) Nouvelles molecules b7-4 et leurs utilisations
WO1999016889A1 (en) Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment
DE60127933D1 (de) Chimäre proteine und anwendungen
YU8997A (sh) Prečišćen protein koji ima serinsku proteaznu inhibitorsku aktivnost i farmaceutski preparat koji ga sadrži
DE69429260D1 (de) Adenovirale vektoren tierischen ursprungs und ihre verwendung bei der gentherapie
DE69633175D1 (de) Multimere proteine
US6313091B1 (en) Pharmaceutical compositions containing TSG-6 for treating inflammatory diseases and cancer-related pathologies and method
NL8921262A (nl) Neutrofiel-activerend peptide-2, werkwijzen voor het bereiden van deze factor en preparaten die dit peptide bevatten.
EP1070085A1 (de) Duale avb3 und metastase-assoziierte rezeptor liganden
DE60031418D1 (de) 15571, ein neues gpcr-ähnliches molekül der secretin-ähnlichen familie und dessen verwendungen
FR2724320B1 (fr) Nouvel implant pour le traitement des maladies acquises
Shi et al. Expression, purification, and characterization of scar tissue neovasculature endothelial cell-targeted rhIL10 in Escherichia coli
DE60237613D1 (de) Neue pgc-1-isoformen und deren verwendungen
ES2198879T3 (es) Metodo para replegar angiostatina.
ATE151777T1 (de) Modifizierter plättchenfaktor-4
Murphy Protein engineering and design for drug delivery
DE60142356D1 (de) 18480 humane proteinkinasemoleküle und ihre verwendungen
EP1104304A1 (de) Multivalent avb3 und ligande für metastasis-assoziierte receptoren
NO20014011L (no) Glukosedehydrogenasefusjonsproteiner og deres anvendelse i ekspresjonssystemer
DE60124910D1 (de) Menschliche twik-8 moleküle und ihre verwendung
ATE476194T1 (de) Ein mitglied der menschlichen proteinkinasefamilie, und verwendungen dafür
RU96122485A (ru) Ангиостатин и способ его использования для ингибирования ангиогенеза

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties